Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
CURRICULUM VITAE INFORMAZIONI PERSONALI Nome Luogo e Data di nascita Codice Fiscale Qualifica Giampiero Girolomoni Montefelcino (PU), 26/04/1957 GRLGRP57D26F497Q Professore ordinario di Dermatologia e Venereologia, Facoltà di Medicina e Chirurgia, Università di Verona; Direttore scuola di specializzazione in Dermatologia e Venereologia, Università di Verona; Direttore della Clinica Dermatologica dell’Azienda Ospedaliera Universitaria Integrata di Verona Numero telefonico dell’ufficio 045/8122547 Fax dell’ufficio 045/8027315 E-mail istituzionale [email protected] TITOLI DI STUDIO E PROFESSIONALI ED ESPERIENZE LAVORATIVE Titolo di studio 1976 Diploma di maturità classica - Liceo Mamiani, Pesaro 1983 Laurea in Medicina e Chirurgia – Università di Modena Altri titoli di studio e 1986 Specialista in Dermatologia e Venereologia- Università di Modena professionali Esperienze professionali (incarichi ricoperti) 1988-1990 Immunodermatology Fellow, Visiting Instructor, Dipart. di Dermatologia, University of Texas Southwestern Medical School, Dallas (TX, USA). 1990-1994 Assistente Medico, Clinica Dermatologica, Università di Modena 1994-2004 Direttore Laboratorio di Ricerca di Immunologia; Primario Seconda Divisione di Dermatologia, Direttore Dipartimento di Dermatologia Clinica, Istituto Dermopatico dell'Immacolata, Roma Capacità linguistiche Attività Scientifiche Ottima conoscenza scritta e parlata della lingua Inglese Fisiopatologia delle reazioni immunitarie cellulo-mediate della cute, immunofarmacologia delle malattie infiammatorie croniche della cute. Dermatologia clinica: malattie cutanee nell’immunodepresso, reazioni cutanee da farmaci, manifestazioni cutanee delle malattie interne, complicanze cardio-metaboliche delle malattie infiammatorie croniche. Esperienze acquisite nel settore scientifiche oggetto di sperimentazione secondo le norme di Buona Pratica Clinica (GCP), maturate nell’ambito degli studi clinici nonché dell’assistenza ai pazienti. Presidente Società Italiana di Dermatologia (Sidemast). Editor in chief di Clinical Dermatology e del Giornale Italiano di Dermatologia e Venereologia. Associate Editor di Frontiers in Medicine (Dermatology). Presidente e/o responsabile scientifico di 102 congressi nazionali o internazionali. Letture a invito 1988-2015: 710. 1 Pubblicazioni Scientifiche Co-autore di 285 articoli originali, 145 rewiew, 80 capitoli di libri o monografie, 900 abstracts per congressi, e co-autore o co-editore di 5 libri. IF globale >1300; Citazioni >15000; H-index: 70; i10 index: 224. PRINCIPALI PUBLICAZIONI 2013-2015: 1. Gisondi P, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Tomino C, Picardo M, Girolomoni G, Naldi L. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare registry. J Eur Acad Dermatol Venereol 27:e30-41, 2013. 2. Tessari G, Naldi L, Boschiero L, Minetti E, Sandrini S, Nacchia F, Valerio F, Rugiu C, Sassi F, Gotti E, Fonte L, Talamini G, Girolomoni G. Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study. Am J Transplant 13:214-221, 2013. 3. Gisondi P, Lora V, Bonauguri C, Russo A, Lippi G, Girolomoni G. Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. Br J Dermatol 168:749-755, 2013. 4. Paller AS, Mercy K, Kwasny MJ, Choon SE, Cordoro KM, Girolomoni G, Menter A, Tom WL, Mahoney AM, Oostveen AM, Seyger MM. Association of pediatric psoriasis severity with excess and central adiposity: an international crosssectional study. JAMA Dermatol 149:166-176, 2013. 5. Gisondi P, Del Giglio M, Girolomoni G. The expectations of patients with psoriasis during office consultation. Clinical Dermatology 1:2-7, 2013. 6. Gisondi P, Tessari G, Di Mercurio M, Del Giglio M, Girolomoni G. Survival of systemic drug therapy for psoriasis. Clinical Dermatology 1:8-14, 2013. 7. Gisondi P, Conti A, Galdo G, Piaserico S, De Simone, C, Girolomoni G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol 168:1124-1127, 2013. 8. Strohal R, Chimenti S, Vena GA, Girolomoni G. Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence. J Dermatolog Treat 24:199-208, 2013. 9. Gisondi P, Girolomoni G. Impact of TNFselected skin disease. G It Dermatol Venereol 148:243-248, 2013. 10. Lora V, Bonaguri C, Gisondi P, Sandei F, Battistelli L, Russo A, Melegari A, Trenti T, Lippi G, Girolomoni G. Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab. Immunol Res 56:382-389, 2013. 11. Esposito M, Gisondi P, Cassano N, Ferrucci G, Del Giglio M, Loconsole F, Giunta A, Vena GA, Chimenti S, Girolomoni G. Survival rate of anti-TNF alpha treatments for psoriasis in routine dermatological practice: a multicenter observational study. Br J Dermatol 169:666-672, 2013. 12. Girolomoni G, Rosina P. Cutaneous vasculitides and vasculopathies. Clinical Dermatology 1:93-97, 2013. 13. Pezzolo E, Colato C, Del Giglio M, Tessari G, Girolomoni G. Acantolytic dyskeratotic acanthoma: case report with literature review. Clinical Dermatology 1:149-152, 2013. 14. Gisondi P, Girolomoni G. Cardio-metabolic comorbidities, the fingerprint of psoriasis. Inter Emerg Med 8:S155-S159, 2013. 15. Bosco L, Schena D, Colato C, Biban P, Girolomoni G. Coma blisters in children: case report and review of the literature. J Child Neurol 28:1677-1680, 2013. 16. Fostini A, Girolomoni G, Tessari G. Prurigo nodularis: an update on etiopathogenesis and therapy. J Dermatolog Treat 24:458-462, 2013. 17. Girolomoni G, Peserico A, Altomare G, Ayala F, Berardesca E, Calzavara Pinton P, Chimenti S, Martini P, Polistena B, Puglisi Guerra A, Vena GA, Spandonaro F. 2 Quality of life in patients with plaque psoriasis treated with biologic therapies. Clinical Dermatology 1:175-182, 2013. 18. Gisondi P, Amerio P, Peserico A, Piaserico S, Potenza C, Bardazzi F, Bongiorno MR, Caproni M, Costanzo A, Loconsole F, Malagoli P, Amoruso G F, Antonucci V A, Bruni P, Campanati A, Carlesimo M, Carrera C G, Cianchini G, Cimmino G, Cozzani E, Dapavo P, D’Amico D, De Simone C, Del Giglio M, Di Nuzzo S, Gai F, Galluccio A G, Goffredo A, Gualdi G, Guarneri C, Kokelj F, Lasagni C, Longo V, Miracapillo A, Mugheddu C, Parodi A, Pellegrino M, Pistone G, Plumari A, Stingeni L, Strippoli D, Travaglini M, Girolomoni G. Uso ottimale dei trattamenti sistemici per la psoriasi moderata-severa. Raccomandazioni per lo “switching” ed il “transitioning”. G It Dermatol Venereol 148 (Suppl 1):1-10, 2013. 19. Nocini PF, Procacci P, Albanese M, Trevisiol L, D'Agostino A, Girolomoni G, Palma P, Chiarini L, Bertossi D. Tongue flap to treat a severe case of Miescher's cheilitis granulomatosa. Minerva Stomatol 62(suppl 1):79-86, 2013. 20. Gisondi P, Targher G, Cagalli A, Girolomoni G. Hyperuricemia in patients with chronic plaque psoriasis. J Am Acad Dermatol 70:127-130, 2014. 21. Gisondi P, Sala P, Alessandrini F, Avesani V, Zoccatelli G, Beltramello A, Moretto G, Gambina G, Girolomoni G. Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis. Dermatology 228:78-85, 2014. 22. Ponti G, Ruini C, Girolomoni G, Pellacani G, Farnetani F, Pastorino L, Ghiorzo P, Witkowski AM, Bianchi-Scarrà G, Tomasi A, Loschi P, Nasti S. Brooke-Spiegler syndrome tumor spectrum beyond the skin: a patient carrying germl ine R936X CYLD mutation and a somatic CYLD mutation in Brenner tumor. Future Oncol 10:345-350, 2014. 23. Paul C, Puig L, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G Nicolas JF, Rizova E, Lavie F, Mistry S, Bergmans P, Barker J, Reich K. Transition to ustekinumab in patients with moderate to severe psoriasis and inadequate response to methotrexate: a randomised clinical trial (TRANSIT). Br J Dermatol 170:425-434, 2014. 24. Reich K, Puig L, Paul C, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Brunori B, Mistry S, Bergmans P, Barker J. One year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomised trial in moderate-to-severe plaque psoriasis. Br J Dermatol 170:435-444, 2014. 25. Augustin M, Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, Gniadecki R, Iversen L, Menter A, Michaelis-Wittern K, Morita A, Nakagawa H, Reich K. Nail assessment in psoriasis and psoriatic arthritis (NAPPA): Development and validation of a tool for assessment of nail psoriasis outcomes. Br J Dermatol 170:591-598, 2014. 26. Daudén E, Bewley A, Lambert J, Girolomoni G, Cambazard F, Reich K. Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis. J Eur Acad Dermatol Venereol 28 (Suppl 2), 22–32, 2014. 27. Fiorino G, Girolomoni G, Lapadula G, Orlando A, Danese S, Olivieri I. The use of biosimilars in immune-mediated disease: a joint Italian Rheumatologic Society (SIR), Italian Society of Dermatology (SIDEMAST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev 13:751755, 2014. 28. Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh AF, Langley RG, Paul CF, Puig L, Reich K, van de Kerkhof PC. Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. J Am Acad Dermatol 70:871-881, 2014. 29. Blandizzi C, Gionchetti P, Armuzzi A, Caporali R, Chimenti S, Cimaz R, Cimino 3 L, Lapadula G, Lionetti P, Marchesoni A, Mennini FS, Salvarani C, Girolomoni G. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol 27 (Suppl 1):1-10, 2014. 30. Armuzzi A, Lionetti P, Blandizzi C, Caporali R, Chimenti S, Cimino L, Gionchetti P, Girolomoni G, Lapadula G, Marchesoni A, Mennini FS, Salvarani C, Cimaz R. Anti-TNF agents as a therapeutic choice in immune-mediated disease. Int J Immunopathol Pharmacol 27 (Suppl 1):11-32, 2014. 31. Lapadula G, Marchesoni A, Armuzzi A, Blandizzi C, Caporali R, Chimenti S, Cimaz R, Cimino L, Gionchetti P, Girolomoni G, Lionetti P, Mennini FS, Salvarani C. Adalimumab in the treatment of immune-mediated diseases. Int J Immunopathol Pharmacol 27 (Suppl 1):33-48, 2014. 32. Schena D, Farina A, Colato C, Girolomoni G. Wells’ syndrome in children: two case reports with review of the literature. Clinical Dermatology 2:51-56, 2014. 33. Cozzi A, Doria A, Gisondi P, Girolomoni G. Skin rash and arthritis syndromes: an appraisal of less common associations. J Eur Acad Dermatol Venereol 28:679-688, 2014. 34. Spandonaro F, Ayala F, Berardesca E, Chimenti S, Girolomoni G, Martini P, Peserico A, Polistena B, Puglisi Guerra A, Vena GA, Altomare G, Calzavara Pinton P. The cost-effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy. BioDrugs 28:285295, 2014. 35. Weisz GM, Albury RW, Matucci-Cerinic M, Girolomoni G, Lippi D. Skin disease in the Medici family and the illness of Contessina de' Bardi de' Medici: a dermatological puzzle. Int J Dermatol 53:786-788, 2014. 36. Pastore S, Lulli D, Girolomoni G. Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Arch Toxicol 88:1189-1203, 2014. 37. Gisondi P, Dalle Vedove C, Girolomoni G. Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy. Dermatol Ther (Heidelb) 41:1-9, 2014. 38. Gisondi P, Targher G, Bardazzi F, Conti A, Donelli S, Di Lernia VG, Di Nuzzo S, Lasagni C, Girolomoni G. Pharmacological treatment of moderate-severe psoriasis in patients with cardio-metabolic comorbidities. G It Dermatol Venereol 149 (Suppl 2):7-11, 2014. 39. Sampogna F, Linder D, Piaserico S, Altomare G, Bortune M, Calzavara –Pinton P, Dalle Vedove C, Girolomoni G, Peserico A, Sala R, Abeni D. Quality of life assessment of patients with scalp dermatitis using the Italian version of the scalpdex. Acta Derm Venereol 94:411-414, 2014. 40. Tessari G, Cagalli A, Girolomoni G. Opportunistic deep cutaneous mycoses in solid organ transplant recipients. G It Dermatol Venereol 149:417-422, 2014. 41. Zanniello R, Leone L, Maurelli M, Colato C, Girolomoni G. Unilaterlal nevoid telangectasia of pregnancy. Clinical Dermatology 2:106-109, 2014. 42. Altomare G, Ayala F, Bardazzi F, Bellia G, Chimenti S, Colombo MD, Flori ML, Girolomoni G, Micali G, Parodi A, Peris K, Vena GA. Consensus on the use of cyclosporine in dermatological practice. G It Dermatol Venereol 149:607-625, 2014. 43. Gisondi P, Girolomoni G. The “difficult patient with psoriasis”, i.e. patient with moderate to severe psoriasis and metaboilic comorbidities. G It Dermatol Venereol 149 (suppl 1):67-69, 2014. 44. Gisondi P, Pezzolo E, Lo Cascio G, Girolomoni G. Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy. Br J Dermatol 171:884-890, 2014. 45. Rosina P, Papagrigoraki A, Zanniello R, Colato C, Girolomoni G. Red eczematous melanoma: a case report with review of the literature. Clinical Dermatology 2:140-143, 2014. 46. Vena GA, Cassano N, Esposito M, Gisondi P, Giunta A, Chimenti S, Girolomoni G. Some considerations about the importance of alliance between patients and 4 dermatologists in psoriasis. Clinical Dermatology 2:147-151, 2014. 47. Strohal R, Kirby B, Puig L; Psoriasis Expert Panel, Girolomoni G, Kragballe K, Luger T, Nestle FO, Prinz JC, Ståhle M, Yawalkar N. Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 28:1661-1669, 2014. 48. Pezzolo E, Peroni A, Schena D, Girolomoni G. Pre-heated autologous serum skin test in localized heat urticaria. Clin Exper Dermatol 39:921-923, 2014. 49. Adami S, Cavani A, Rossi F, Girolomoni G. The role of IL-17 in psoriatic disease. BioDrugs 28:487-497, 2014. 50. Peroni A, Colato C, Rongioletti F, Girolomoni G. Histiocytoid Sweet syndrome is infiltrated predominantly by M2-like macrophages. J Am Acad Dermatol 71:131-139, 2015. 51. Scalone L, Cortesi PA, Mantovani LG, Belisari A, Ayala F, Fortina AB, Bonamonte D, Borroni G, Cannavò SP, Guarneri F, Cristaudo A, De Pità O, Gallo R, Girolomoni G, Gola M, Lisi P, Pigatto PD, Satta R, Giannetti A. Clinical epidemiology of hand eczema in patients accessing dermatological referall centres: results from a Mediterranean country. Br J Dermatol 172:187-195, 2015. 52. Gisondi P, Galvan A, Idolazzi L, Girolomoni G. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front Med (Lausanne) 2015;2:1. doi: 10.3389/fmed.2015.00001. eCollection 2015 53. Zimmermann M, Bianchetto Aguilera F, Castellucci M, Rossato M, Costa S, Lunardi L, Ostuni R, Girolomoni G, Natoli G, Bazzoni F, Tamassia N, Cassatella MA. Chromatin remodelling and autocrine TNF are required for optimal interleukin-6 expression in activated human neutrophils. Nat Commun 6:6061, 2015. doi: 10.1038/ncomms7061 54. Zaza G, Ferraro PM, Tessari G, Sandrini S, Scolari MP, Cappelli I, Minetti E, Gesualdo L, Girolomoni G, Gambaro G, Lupo A, Boschiero L. Predictive model for delayed graft function based on easily available pre-renal transplant variables. Inter Emerg Med 10:135-141, 2015. 55. Rosina P, Giordano MV, Papagrigoraki A, Tessari G, Girolomoni G. Videodermatoscopic follow up of melanocytic lesions: a retrospective clinical study. Clinical Dermatology 3:7-12, 2015. 56. Gisondi P, Perazzoli G, Del Giglio M, Girolomoni G. Systemic therapy of psoriasis in diabetic patients. Glob Dermatol 2:112-116, 2015. 57. Gisondi P, Cazzaniga S, Chimenti S, Maccarone M, Picardo M, Girolomoni G, Naldi L. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare registry. Br J Dermatol 172:1613-1620, 2015. 58. Girolomoni G, Griffiths CEM, Krueger J, Nestle F, Nicolas J-F, Prinz JC, Puig L, Ståhle M, van de Kerkhof PCM, Allez M, Emery P, Paul C. Early intervention in psoriasis and immune-mediated inflammatory diseases: a hypothesis paper. J Dermatolog Treat 26:103-112, 2015. 59. Girolomoni G, Altomare G, Ayala F, Berardesca E, Calzavara Pinton P, Chimenti S, Martini P, Peserico A, Puglisi Guerra A, Vena GA. Differential management of biologic drugs in mild-to-severe psoriasis patients: an Italian Delphi consensus expert panel. J Dermatolog Treat 26:128-133, 2015. 60. Gisondi P, Bardazzi F, Conti A, Dapavo P, Di Nuzzo S, Malagoli P, Piaserico S, Strippoli D, Girolomoni G. Pharmacoeconomic considerations in the treatment of psoriatic arthritis with biologics: focus on golimumab. Clinical Dermatology 3 (Suppl 1):1-8, 2015. 61. Pelissero A, Russi EG, Melano A, Filini C, Vigna-Taglianti R, Settineri N, Lucio F, Girolomoni G, Pergolizzi S. Facial basal cell carcinomas treated with hypofractionated radiotherapy: A retrospective analysis in 117 elderly patients. J Am Acad Dermatol 73:166-168, 2015. 62. Mrowietz U, Leonardi C, Girolomoni G, Toth D, Morita A, Balki SA, 5 Szepietowski JC, Regnault P, Thurston H, Papavassilis C. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate-to-severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol 73:27-36, 2015. 63. Gisondi P, Girolomoni G. Skin moisturization for xerosis related to targeted anticancer therapies. J Am Acad Dermatol 73:e33, 2015. 64. Genazzani A, Altomare G, Balato N, Cusano F, De Pità O, Loconsole F, Micali G, Piaserico S, Girolomoni G. Biosimilar infliximab: an expert view. G It Dermatol Venereol 150:449-459, 2015. 65. Lubrano E, Cantini F, Costanzo A, Girolomoni G, Prignano F, Olivieri I, Scarpa R, Spadaro A, Atzeni F, Narcisi A, Ricceri F, Sarzi-Puttini P. Measuring psoriatic disease in clinical practice. An expert opinion position paper. Autoimmun Rev 14:864-874, 2015. 66. Cozzi A, Colato C, Biasi D, Girolomoni G. Adult Still’s disease: case report with literature review on the cutaneous manifestations. Clin Rheumatol 00:000000, 2015. 67. Vena GA, Gisondi P, Cassano N, Girolomoni G. La “cross unit” per ottimizzare il trattamento topico della psoriasi. G It Dermatol Venereol 149 (Suppl 3):0000, 2015. 68. Pezzolo E, Girolomoni G, Gisondi P. Glomerular filtration rate in patients with psoriasis candidate to systemic treatment. J Int Med Res 00:000-000, 2015. 69. Gisondi P, Di Mercurio M, Idolazzi L, Girolomoni G. The concept of remission in chronic plaque psoriasis. J Rheumatol 00:000-000, 2015. 70. Schena D, Tessari G, Galvan A, Girolomoni G. Clinical features and course of cutaneous mastocytosis on 133 children. Br J Dermatol 00:00-00, 2015 71. Altomare G, Ayala F, Bardazzi F, Bellia G, Chimenti S, Colombo D, Flori ML, Girolomoni G, Micali G, Parodi A, Peris K, Vena GA. Cyclosporine in psoriasis: comparison of a 25-year real world Italian experience to current European guidelines. G It Dermatol Venereol 151:00-00, 2015. 72. Presta F, Del Giglio M, Girolomoni G. A new case of semicircular lipoatrophy with review of the literature. G Ital Dermatol Venereol 151:000-000, 2015. 73. Di Mercurio M, Gisondi P, Colato C, Girolomoni G. Annular lichenoid dermatitis of youth (ALDY): report of six new cases with review of the literature. Dermatology 000:000-000, 2015. 74. Augustin M, Blome C, Paul C, Puig L, Luger T, Lambert J, Chimenti S, Girolomoni G, Kragballe K, Naessens D, Bergmans P, Smirnov P, Barker J, Reich K. Assessment of patient benefit following transition from methotrexate to ustekinumab in psoriasis patients: a sub-analysis of the TRANSIT study. J Eur Acad Dermatol Venereol 30:000-000, 2015. 75. van de Kerkhof PCM, Reich R, Kavanaugh A, Bachelez H, Barker J, Girolomoni G, Langley R, Paul CF, Puig L, Lebwohl M. Physician perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. J Eur Acad Dermatol Venereol 30:000-000, 2015. 76. Strohal R, Prinz J, Girolomoni G, Nast A. A patient-centred approach to biologic treatment decision making for psoriasis: an expert consensus. J Eur Acad Dermatol Venereol 30:000-000, 2015. 77. Rongioletti F, Kaiser F, Cinotti E, Metze D, Battistella M, Girolomoni G, Calzavara-Pinton P, André J, Kempf W, Damewska K, Cavelier-Balloy B. Scleredema: A multicenter study of characteristics, comorbidities, course and therapy in 44 patients. J Eur Acad Dermatol Venereol 30:000-000, 2015. 78. Fostini A, Girolomoni G. Experimental elicitation of itch: evoking and evaluation techniques. J Dermatol Sci 00:000-000, 2015. 79. Spandonaro F, Ayala F, Berardesca E, Chimenti S, Girolomoni G, Martini P, Peserico A, Polistena B, Puglisi Guerra A, Vena GA, Altomare G, Calzavara Pinton P. The impact of biologic therapies for chronic plaque psoriasis in a societal perspective: an analysis based on Italian real-world clinical practice. J 6 Eur Acad Dermatol Venereol 30:000-000, 2015. 80. Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol 00:00-00, 2015. 81. Russi EG, Moretto F, Rampino M, Benasso M, Bacigalupo A, De Sanctis V, Numico G, Bossi P, Buglione M, Lombardo A, Airoldi M, Merlano MC, Licitra L, Denaro N, Pergolizzi S, Pinto C, Bensadoun RJ, Girolomoni G, Langendijk JA. Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. Crit Rev Oncol Hematol 00:000-000, 2015. 82. Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, Gniadecki R, Iversen L, Menter A, Michaelis-Wittern K, Morita A, Nakagawa H, Reich K, Augustin M. Patient-relevant needs and treatment goals in nail psoriasis. Qual Life Res 00:000-000, 2015. 83. Barba A, Colato C, Girolomoni G. Intralymphatic hystiocytosis: case report with literature review. J Cutan Pathol 00:000-000, 2015. 84. Sabbadini C, Banzato C, Schena D, Peroni D, Colato C, Girolomoni G. Metastatic Crohn’s disease in childhood: case report with review of the literature. J Dtsch Dermatol Ges 14:000-000, 2015. Autorizzo il trattamento dei dati personali ai sensi del D. Lgs N. 196/2003 “Codice in materia di protezione dei dati personali”. Verona, 31.08.2015 Prof. Giampiero Girolomoni 7